Earnings Call Summary | Harvard Bioscience(HBIO.US) Q2 2024 Earnings Conference
Earnings Call Summary | Harvard Bioscience(HBIO.US) Q2 2024 Earnings Conference
Operating profit on an adjusted basis was $800,000 or 3.5% of revenue, with adjusted The following is a summary of the Harvard Bioscience, Inc. (HBIO) Q2 2024 Earnings Call Transcript:
以下是哈佛生物科學公司（HBIO）2024年Q2業績會簡報：
Financial Performance:
金融業績：
Harvard Bioscience reported Q2 2024 revenue of $23.1 million, down $5.7 million from the previous year.
Gross margin for Q2 2024 was 57.2%, slightly lower than last year's 58% due to lower absorption of fixed manufacturing costs.
Operating profit on an adjusted basis was $800,000 or 3.5% of revenue, with adjusted EBITDA at $1.3 million or 5.5% of revenue.
Cash flow from operations for the first half of 2024 was $0.6 million, significantly lower compared to $5.4 million in the same period last year.
哈佛生物科學報告2024年Q2營業收入爲2310萬美元，較去年同期下降570萬美元。
2024年Q2毛利率爲57.2%，略低於去年的58%，因固定制造成本吸收量下降。
調整後的營業利潤爲80萬美元，佔營業收入的3.5%，調整後的EBITDA爲130萬美元，佔營業收入的5.5%。
2024年上半年經營活動產生的現金流爲60萬美元，較去年同期的540萬美元顯著降低。
Business Progress:
業務進展：
The company indicated a shift towards product innovation with new telemetry devices and neurobehavioral monitoring systems expected to boost revenues.
Commercial introduction of new products in electroporation and bioproduction projects, along with a CGMP-compliant amino acid analysis system for bioprocessing applications.
Installation of MEA Organoid platforms for in-vitro data acquisition, particularly in neuro and cardiac toxicology applications, setting up a full production launch in Q1 2025.
公司表示將轉向產品創新，新增遙測設備和神經行爲監測系統預計將提振收入。
推出新電穿孔和生產項目產品，以及符合CGMP的氨基酸分析系統用於生物加工應用。
安裝MEA器官樣板平台進行體外數據獲取，尤其是在神經和心臟毒理學應用方面，將於2025年Q1開展全面生產發行。
Opportunities:
機會：
New product launches and innovations set to contribute to revenue streams and underpin long-term double-digit growth.
Increased quoting and funnel activity in China and Asia Pacific signals potential revenue stabilization and growth from academic sectors.
新產品的推出和創新有望爲收入流提供支撐，並支持長期兩位數的增長。
中國和亞洲太平洋地區的增加的報價活動和漏斗活動預示着學術領域的潛在收入穩定和增長。
Risks:
風險：
Continued challenges from lower capital spending by CROs and pharma in the US and Europe affecting preclinical product shipments.
Economic factors including interest rates and energy costs additionally constrain spending in Europe.
美國和歐洲CRO和製藥公司資本支出的下降對臨床前產品出貨構成持續挑戰。
利率期貨和能源成本等經濟因素也限制了歐洲的支出。
More details: Harvard Bioscience IR
更多詳細信息：哈佛生物科學IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由AI生成。文章內容的準確性無法完全保證。有關更全面的詳細信息，請參閱IR網站。本文只是爲投資者提供參考，沒有任何指導或推薦建議。